Product analysis
MK-7 Vitamin K-2 100 mcg supports normal bone-related processes by helping activate proteins involved in bone mineral use.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality100
Vitamin K is supplied as MK-7, a favorable form choice. The form alone does not establish a special health advantage over other vitamin K options.
Ingredient Transparency100
Both the vitamin K amount and MK-7 form are clearly identified. That makes comparison with other vitamin K servings straightforward.
Value For Money100
MK-7 offers good value at the serving price. The clearly identified serving makes that cost comparison useful.
Customer Satisfaction94
Customer ratings are generally positive. A large number of ratings gives a broader picture of customer satisfaction.
Product Focus70
The single nutrient has a clear role in normal bone and clotting processes. Possible effects on blood-vessel stiffness come from specific groups and longer-term use, so broader heart benefits remain uncertain.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $0.11
- Also available
MK-7 Vitamin K-2 100 mcg$19.93- Customer rating
- 4.8 · 31,809 ratings
Goals
Impact
High effect
Vitamin K · 100 mcg
MK-7 has limited evidence for improving arterial stiffness in healthy postmenopausal women. This is a narrower finding than preventing calcium deposits or cardiovascular events. The declared amount provides a partial comparison with studied exposure, and a single serving does not establish the sustained use involved in the evidence.
How this product is rated for Heart Health
Ingredient fit72
Vitamin K provides the main connection to heart health; other active ingredients broaden the formula beyond this goal
Goal fit
Vitamin K provides the main connection to heart health; other active ingredients broaden the formula beyond this goal
Dose adequacy
The relevant amounts provide a partial contribution across the formula; higher amounts are not automatically more beneficial.
Pathways19
Arterial calcification control is the strongest connection in the saved findings; this describes the ingredient roles, not a guaranteed effect.
Depth
Arterial calcification control is the strongest connection in the saved findings; this describes the ingredient roles, not a guaranteed effect.
Breadth
The formula does not meaningfully span the compared lipid, vascular and homocysteine areas.
Evidence77
Vitamin K provides the strongest relevant evidence here, with the population and benefit limits described above.
Evidence strength
Vitamin K provides the strongest relevant evidence here, with the population and benefit limits described above.
Studied preparation
The contributing ingredient preparations match those recognized in the supplied comparison; this does not establish efficacy of the finished product.
Formulation logic100
The relevant ingredients do not depend on a missing partner in the supplied findings. No configured ingredient conflict was identified in the supplied findings.
Partner coverage
The relevant ingredients do not depend on a missing partner in the supplied findings.
Conflicts
No configured ingredient conflict was identified in the supplied findings.
Effective doses
The contributing ingredients have meaningful declared amounts for comparison, without proving a cardiovascular benefit.
Impact
High effect
Vitamin K · 100 mcg
Vitamin K as MK-7 helps activate proteins involved in bone mineralization. The 100 mcg serving provides a partial amount compared with the specific longer-term postmenopausal studies in the supplied context. Those findings suggest possible bone-density support in that population, but are mixed and do not establish general fracture prevention. This product addresses bone-protein activation rather than supplying bone minerals.
How this product is rated for Bone Health
Ingredient fit76
MK-7 is directly relevant to bone-protein activation, with partial amount support.
Goal fit
MK-7 is the sole recognized ingredient, with several other goal links.
Dose adequacy
The 100 mcg serving is below the amount in the cited favorable long-term MK-7 study.
Pathways42
Bone-protein activation is the only substantially represented route.
Depth
MK-7 provides the strongest bone-protein activation connection.
Breadth
Mineral supply, calcium regulation and matrix formation are unrepresented.
Evidence98
The supplied MK-7 evidence is specific to longer-term postmenopausal studies and has mixed outcomes.
Evidence strength
MK-7 provides the strongest reviewed evidence present here.
Studied preparation
The explicit MenaQ7 declaration identifies the recognized MK-7 preparation.
Formulation logic100
MK-7 can stand alone, with no matched conflict.
Partner coverage
MK-7 requires no missing companion ingredient.
Conflicts
No matched ingredient conflict is present.
Effective doses
MK-7 meets the saved inclusion threshold.
Impact
High effect
Vitamin K · 100 mcg
Vitamin K supplies a nutrient involved in normal blood clotting and bone-related processes. Its contribution is nutritional, particularly when intake falls short. The MenaQ7 preparation does not establish superiority over other vitamin K forms, and this serving does not establish cardiovascular protection.
How this product is rated for Everyday Health
Ingredient fit74
Vitamin K provide the main relevant nutrients. Their amounts vary in their contribution against the supplied references.
Goal fit
Vitamin K account for the main nutritional connection to general health.
Dose adequacy
Amounts make uneven contributions against the supplied references; smaller or unresolved amounts limit what can be attributed to the serving.
Pathways17
The retained contributions concern a limited bone and mineral contribution. These are nutrient roles, rather than proof of broader health improvement.
Depth
The strongest supplied finding concerns bone and mineral metabolism; this describes nutrient-related support, not a measured health improvement.
Breadth
No area reaches the supplied breadth criterion; vitamin K retains a limited bone and mineral contribution.
Evidence78
Vitamin K leads the retained evidence finding. The practical general-health interpretation remains nutritional support when intake falls short.
Evidence strength
Vitamin K provides the strongest retained evidence finding; its nutritional role does not establish additional benefit above adequate intake.
Studied preparation
The retained preparations match those accepted in the supplied comparison, without establishing that one form is superior.
Formulation logic100
The retained ingredients have no unmet partner requirement or configured conflict. Their amounts meet the supplied minimum comparison criterion.
Partner coverage
The retained ingredients can contribute alone or have their required partner; this does not establish extra benefit from combining them.
Conflicts
No configured ingredient conflict was identified in the supplied findings; this is not a comprehensive safety assessment.
Effective doses
All retained ingredients meet the supplied minimum amount criterion; that criterion is not a proven effective dose.
Impact
High effect
Vitamin K · 100 mcg
MenaQ7 identifies the MK-7 form of vitamin K, which has limited support for selected arterial-stiffness measures. The main trial involved postmenopausal women over three years, with several changes concentrated among those with greater initial stiffness. This 100 mcg serving is below the 180 mcg daily study exposure, and partial amount recognition does not establish cardiovascular-event prevention.
How this product is rated for Cardiovascular Support
Ingredient fit72
Vitamin K is the main recognized ingredient; smaller or unresolved amounts reduce the serving’s contribution.
Goal fit
The recognized ingredients dominate the formula, with links to other goals reducing its cardiovascular specificity.
Dose adequacy
Smaller or unresolved ingredient quantities limit the serving’s amount contribution; partial recognition does not establish a measured dose-response.
Pathways19
The strongest assigned contribution concerns arterial calcification control. Other cardiovascular mechanisms have less or no assigned coverage.
Depth
The strongest assigned support concerns arterial calcification control, rather than comprehensive cardiovascular protection.
Breadth
No mechanism reaches the coverage threshold.
Evidence69
Vitamin K leads the evidence findings. The supplied population and preparation limits remain relevant to expectations.
Evidence strength
Vitamin K provides the leading evidence contribution; its marker findings do not establish prevention of cardiovascular events.
Studied preparation
The counted preparations are recognized as studied, with the population and exposure distinctions described for the relevant ingredients.
Formulation logic100
The counted ingredients have no unmet partner requirement or identified configured conflict; amount thresholds are considered separately.
Partner coverage
No unmet partner requirement is identified for the counted ingredients; combining them does not establish an added benefit.
Conflicts
No configured ingredient conflict was identified.
Effective doses
All counted ingredients clear the minimum amount threshold, which is distinct from a proven effective dose.
Impact
High effect
Vitamin K · 100 mcg
Selected arterial-stiffness findings concern identified MenaQ7 MK-7 in postmenopausal women, rather than all vitamin K forms.
How this product is rated for Longevity
Ingredient fit76
Vitamin K provide the main connections, although relevance depends on the specific preparation and serving amount.
Goal fit
Vitamin K provides the relevant ingredient connection.
Dose adequacy
The declared serving amounts provide uneven contributions; the amount comparison does not establish a proven anti-aging dose.
Pathways42
The saved findings concentrate on selected functional or antioxidant-related processes rather than broad preservation of aging-related function.
Depth
The strongest represented area is arterial calcification control. This describes ingredient roles rather than demonstrated slowing of aging.
Breadth
The represented areas meeting the comparison threshold are arterial calcification control.
Evidence80
The human findings concern narrow outcomes and particular preparations or populations, rather than human lifespan extension.
Evidence strength
Vitamin K supplies the leading evidence contribution, with benefits limited by the populations and outcomes studied.
Studied preparation
The qualifying ingredient preparations match the saved comparison; this does not extend results to broader aging outcomes.
Formulation logic100
The contributing ingredients meet the supplied partner requirements; the configured check identifies no conflict.
Partner coverage
The contributing ingredients can act independently or have the partners required by the supplied findings.
Conflicts
No configured ingredient conflict was identified; this is a limited interaction check.
Effective doses
All contributing ingredients meet the amount threshold used for this comparison, which is not a proven anti-aging dose.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin K-2 (Menaquinone-7) | 100 mcg |
Vitamin K (Menaquinone-7) · 100 mcg OverallScore93
The serving provides 100 mcg of MK-7 at a low cost per serving. It uses vitamin K2 as MK-7. The MK-7 trans form is not specified.
How this ingredient is rated
Active Ingredient Quality & Bioavailability82
It uses vitamin K2 as MK-7. MK-7 is named, but its trans form is not specified.
Vitamin K Form (MK-7 vs. MK-4 vs. K1)
It uses vitamin K2 as MK-7.
MK-7 Isomer Disclosure
MK-7 is named, but its trans form is not specified.
Dose, Safety & Label Transparency100
The serving provides 100 mcg of MK-7. The vitamin K amount and form are stated.
Vitamin K2 (MK-7) Dosage Efficacy
Each serving provides 100 mcg of MK-7.
Form and Subtype Transparency
The vitamin K amount and form are stated.
Value100
The cost per serving is low.
Price per Effective MK-7 Serving
The cost per serving is low.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
- Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
- Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
- Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
- Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
- Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
- Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
- Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
- Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.
- Dietary vitamin K intake associates with reduced all-cause mortality in non-alcoholic fatty liver disease patients.
- Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts.
- The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients.
- Effect of vitamin K on improving post‑kidney transplant outcomes: a meta‑analysis.
- Vitamin K1 intake is associated with lower risk for all-cause and cardiovascular disease mortality in community-dwelling older Australian women.
- The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial.
- Topical Menaquinone‑7 (Vitamin K2, MK-7) as a Mitochondrial Bioenergetic Activator for Skin Anti-Aging: Mechanistic Evidence in Skin Cells and a Randomized Split-Face/Neck Study.
- Vitamin K status and cognitive function in healthy older adults.
- High dephospho-uncarboxylated matrix Gla protein concentrations, a plasma biomarker of vitamin K, in relation to frailty: the Longitudinal Aging Study Amsterdam.
- Vitamin K Concentration and Cognitive Status in Elderly Patients on Anticoagulant Therapy: A Pilot Study.